Axsome Therapeutics, Inc. 8-K

What Happened

• Axsome Therapeutics, Inc. announced on January 12, 2026 (via Form 8-K) that it issued a press release titled “Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue,” reporting preliminary net product revenue for Q4 and the full year 2025. The Form 8-K was signed by President and CEO Herriot Tabuteau, M.D.

Key Details

• Filing date: January 12, 2026 (Form 8-K, Items 2.02 and 8.01).
• Subject: Preliminary fourth quarter and full-year 2025 net product revenue (reported in a press release).
• Exhibit: Press release is attached as Exhibit 99.1 to the filing.
• The 8-K reports the release of preliminary revenue information; it does not replace final audited financial statements or formal earnings filings.

Why It Matters

• Revenue updates are material to investors because they reflect recent sales performance and can affect stock valuation and near-term expectations for Axsome’s products.
• The information is labeled preliminary, so final reported results (quarterly/annual filings or a formal earnings release) may differ; investors should watch for the company’s complete results and official financial statements for confirmation.